Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1613 1617 1621 1627 1629
This examiner grants 32% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19271284 | PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE | Non-Final OA | scPharmaceuticals Inc. |
| 17792856 | CONCENTRATED SODIUM VALPROATE FOR RAPID DELIVERY | Final Rejection | The Regents of the University of Michigan |
| 19001141 | LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYE | Non-Final OA | Chibi, Inc. |
| 18546258 | TREATMENT OF MYOPIA | Final Rejection | University of Utah Research Foundation |
| 18775105 | MODULATORS OF SK4 POTASSIUM CHANNEL AND USES THEREOF | Non-Final OA | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University |
| 17632419 | Ophthalmic Composition for Promoting Tear Secretion | Final Rejection | Rohto Pharmaceutical Co., Ltd. |
| 17791239 | Use of Statins to Treat or Prevent Drug-Induced Hearing Loss | Non-Final OA | The United States of America, as represented by the Secretary, Dept. of Health and Human Services |
| 18603489 | 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES | Non-Final OA | EXONATE LIMITED |
| 18494545 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | Non-Final OA | Perfuse Therapeutics, Inc. |
| 17934945 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | Final Rejection | Acucela Inc. |
| 17613267 | PI3K/LYN-ACLY Signaling Inhibition | Final Rejection | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center |
| 17792282 | PHARMACEUTICAL COMPOSITION OF TRICYCLIC PDE3/PDE4 DUAL INHIBITOR COMPOUND | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18274647 | TREATMENT OF ASTIGMATISM | Final Rejection | iVeena Delivery Systems, Inc. |
| 17800874 | COMPOSITIONS COMPRISING AXITINIB AND METHODS OF TREATING OCULAR DISORDERS | Final Rejection | Clearside Biomedical, Inc. |
| 18100505 | PHARMACEUTICAL COMPOSITIONS OF MYCOPHENOLIC ACID AND/OR BETAMETHASONE FOR THE TREATMENT OF OCULAR DISORDERS | Non-Final OA | SURFACE OPHTHALMICS, INC. |
| 17924198 | USE OF SYMPATHETIC ACTIVATION INHIBITOR AND/OR ALPHA 1-ADRENERGIC RECEPTOR INHIBITOR IN PREPARING MEDICINE FOR TREATING DRY EYES | Non-Final OA | Eye Institute of Shandong First Medical University |
| 18044149 | Inhibition of Endothelial ETS Family Transcription Factors Promotes Flow-Dependent Ocular Vessel Regression | Non-Final OA | Oklahoma Medical Research Foundation |
| 18114469 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOF | Non-Final OA | Azurity Pharmaceuticals, Inc. |
| 18114410 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOF | Final Rejection | Azurity Pharmaceuticals, Inc. |
| 17261359 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | Non-Final OA | BEIGENE, LTD. |
| 17998370 | METHODS OF TREATING VISUAL DISORDERS USING DAILY LOW DOSING OF A RETINOID COMPOUND | Non-Final OA | ELUMINEX BIOSCIENCES (SUZHOU) LIMITED |
| 17818159 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | Non-Final OA | XORTX THERAPEUTICS, INC. |
| 17868358 | METHODS OF PREPARING COMPOSITIONS CONTAINING THYMOQUINONE | Non-Final OA | Jina Pharmaceuticals, Inc. |
| 17756266 | EYE DROP COMPOSITION FOR PREVENTING OR TREATING EYE DISEASE | Final Rejection | AptaBio Therapeutics Inc. |
| 17640889 | METHODS FOR ALLEVIATING PTERYGIUM-ASSOCIATED WORRY ABOUT EYE APPEARANCE | Non-Final OA | Cloudbreak Therapeutics, LLC |
| 17119000 | USE OF CYSTEAMINE AND DERIVATIVES THEREOF TO TREAT DYSFUNCTIONAL TEAR SYNDROME (DTS) | Non-Final OA | MESHABERASE, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy